PEACE-3 Study Results: Efficacy

An expert discusses the key efficacy findings from the PEACE-3 study, including results on radiographic progression-free survival (rPFS) and overall survival (OS), and offers insights on how to interpret and apply these results in clinical practice.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.Case presentation: Patient with metastatic CRPC after ARPI and docetaxel for localized PC

EP: 2.Therapeutic options for a patient with mCRPC after ADT + docetaxel

EP: 3.PEACE-3 study of enzalutamide + Ra-223 for ARPI-naïve mCRPC: Design and objectives

EP: 4.PEACE-3 Study Results: Study Population & Disposition

Now Viewing

EP: 5.PEACE-3 Study Results: Efficacy

EP: 6.PEACE-3 Study Results: Safety

EP: 7.How would therapeutic options change if this patient was asymptomatic?

EP: 8.Protecting bone health for patients receiving Ra-223 + ARPI combination

EP: 9.Ongoing studies of Ra-223–based combinations

EP: 10.Ongoing studies of Ra- 223–based combinations

What were the key efficacy findings from the PEACE-3 study? How do you interpret and think about the results (eg, rPFS, OS)?

Recent Videos

COMFORT Trials: Applying Evidence to Intermediate-Risk Myelofibrosis

Myelofibrosis Management: Clinical Approaches and Treatment Algorithms With Case-Based Application

Clinical Impact of COCOON: Advancing Dermatologic AE Management

Clinical Decision-Making Framework for Initiating Myelofibrosis Therapy

Clinical Approaches for Dermatologic AEs Associated With Amivantamab + Lazertinib in Advanced NSCLC

Prognostic Stratification on Myelofibrosis: From Models to Clinical Application

Ruxolitinib Therapy for cGVHD: Insights on Patient and Safety Monitoring

Personalized JAK Inhibitor Selection in Myelofibrosis: Clinical Characteristics, Molecular Profiles, and Treatment Sequencing

Advancing Treatment Paradigms in Myeloproliferative Neoplasms: From Molecular Pathogenesis to Patient-Tailored Therapy

Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease